

# Subject Index

- Allelic imbalance, 10 (PP-1-1)
- Aneuploidy, 12 (PP-1-12), 41 (PP-6-19), 42 (PP-6-23), 56 (PP-9-9)
- Angiogenesis, 14 (PP-1-23), 41 (PP-6-16), 55 (PP-9-2), 57 (PP-9-15)
- Angiosarcoma of the breast, 22 (PP-3-12)
- Apoptosis, 12 (PP-1-16)
- Aromatases and estrogen biosynthesis, 53 (PP-8-24)
- bcl-2 gene, 12 (PP-1-16), 55 (PP-9-1), 56 (PP-9-7)
- bcl-2 gene expression, 11 (PP-1-6)
- Biochemical markers: anti-estrogen action, 13 (PP-1-22), 53 (PP-8-24)
- Biochemical markers: peripheral blood, *see* Tumor antigens, uPA
- Body weight, 28 (PP-4-11), 30 (PP-4-22)
- Bone metastases and bone pain, 50 (PP-8-9, PP-8-8), 52 (PP-8-18), 53 (PP-8-23, PP-8-26)
- Bone resorption (*see also* Osteoporosis), 26 (SY-6-3), 35 (PP-5-4), 50 (PP-8-7), 51 (PP-8-17)
- BRCA1 and BRCA2 genes (*see also* Genetic screening), 3 (PL-1), 7 (SY-1-1, SY-1-2), 28 (PP-4-6), 29 (PP-4-15, PP-4-16), 33 (PP-4-38)
- Breast biopsy, 8 (SY-2-4), 29 (PP-4-13)
- Breast self-examination, *see* Physical examination
- c-erbB2 (protein) expression, 7 (SY-1-4), 10 (PP-1-5), 13 (PP-1-18, PP-1-19), 25 (SY-5-1, SY-4-4), 56 (PP-9-7, PP-9-5), 57 (PP-9-15), 58 (PP-9-17)
- c-erbB2 proto-oncogene, 7 (SY-1-4, SY-1-1, SY-1-3), 10 (PP-1-5), 57 (PP-9-11)
- c-int2 proto-oncogene, 7 (SY-1-3), 57 (PP-9-11)
- c-myc proto-oncogene, 57 (PP-9-11)
- CA 15.3, 13 (PP-1-17), 31 (PP-4-23), 42 (PP-6-21)
- Cardiotoxicity, 5 (EP-4), 45 (PP-7-3), 48 (PP-7-16)
- Cathepsin D, 41 (PP-6-18)
- CEA, 13 (PP-1-17), 31 (PP-4-23)
- Comparison studies, 22 (PP-3-11), 35 (PP-5-7), 37 (PP-5-16), 45 (PP-7-1, PP-7-2, PP-7-4), 46 (PP-7-7, PP-7-6), 47 (PP-7-13, PP-7-14), 48 (PP-7-18), 51 (PP-8-14, PP-8-15), 53 (PP-8-28)
- Computed tomography, 29 (PP-4-17)
- Contralateral breast cancer surveillance, 31 (PP-4-26), 32 (PP-4-33)
- Cost:benefit and risk:benefit analysis (screening), 1 (DI-2-2, DI-2-1), 27 (PP-4-4, PP-4-3, PP-4-2), 30 (PP-4-21), 31 (PP-4-25), 33 (PP-4-35), 34 (PP-4-41)
- Cowden disease (gene), 12 (PP-1-15)
- Cyclin D1 protein, 11 (PP-1-8)
- Cytogenetic abnormalities, 11 (PP-1-10)
- Cytokeratins, 58 (PP-9-16)
- Diabetes mellitus, 40 (PP-6-10)
- Digital processing (*see also* Mammography), 32 (PP-4-29)
- DNA cytometry, *see* Aneuploidy
- Ductal carcinoma in situ: diagnosis, 7 (SY-2-1), 8 (SY-2-2, SY-2-4), 20 (PP-3-1), 28 (PP-4-7), 29 (PP-4-13), 30 (PP-4-20), 33 (PP-4-35), 40 (PP-6-12)
- Ductal carcinoma in situ: prognosis and outcome, 7 (SY-2-1), 8 (SY-3-1), 14 (PP-2-2), 20 (PP-3-1, PP-3-2), 21 (PP-3-6), 22 (PP-3-14), 23 (PP-3-16), 27 (PP-4-5), 42 (PP-6-22), 58 (PP-10-2)
- Ductal carcinoma in situ: treatment, 7 (SY-2-1), 8 (SY-2-2, SY-2-3), 18 (PP-2-19), 20 (PP-3-1, PP-3-2), 23 (PP-3-16), 24 (PP-3-20), 38 (PP-6-3), 58 (PP-10-2)
- EGF receptor status, 39 (PP-6-9), 43 (SY-7-3), 54 (PP-8-32), 56 (PP-9-5)
- Endometrial and ovarian cancer, 31 (PP-4-26), 36 (PP-5-8)
- Estrogen receptor radioligands, 30 (PP-4-19)
- Estrogen receptor status, 13 (PP-1-20), 25 (SY-5-1, SY-4-4), 26 (SY-5-2), 30 (PP-4-22), 35 (PP-5-6, PP-5-5), 36 (PP-5-10, PP-5-13), 38 (PP-6-2), 39 (PP-6-9), 41 (PP-6-19, PP-6-15), 42 (PP-6-24), 45 (PP-7-1)
- Estrogen receptors: mutations and polymorphism, 14 (PP-1-26), 43 (SY-7-2)
- Ethnic groups, 11 (PP-1-10), 28 (PP-4-11), 32 (PP-4-30), 55 (PP-9-2)
- Fatty acid synthetase, 56 (PP-9-8)
- Fine needle aspiration biopsy, *see* Breast biopsy
- Genetic screening (*see also* Hereditary breast cancer), 3 (PL-1)
- Germline mutations, 7 (SY-1-2), 28 (PP-4-6), 33 (PP-4-38)
- Growth hormone receptors, 43 (SY-7-4, SY-7-3)
- Guide-wire biopsy, *see* Breast biopsy
- Hereditary breast cancer and familial breast cancer clustering (*see also* Genetic screening), 3 (PL-1), 7 (SY-1-2), 27 (PP-4-4), 28 (PP-4-6, PP-4-7), 29 (PP-4-16), 33 (PP-4-35, PP-4-38), 34 (PP-4-40)
- Histologic grade, 13 (PP-1-19), 28 (PP-4-6), 32 (PP-4-33), 38 (PP-6-2), 39 (PP-6-4, PP-6-5, PP-6-6, PP-6-7), 41 (PP-6-19)
- Hypercalcemia, 41 (PP-6-20)
- IGF-I receptors, 43 (SY-7-3, SY-7-4)
- Immune system function, 11 (PP-1-9)
- In vitro fertilization, 28 (PP-4-9)
- Infiltrating lobular carcinoma, 54 (PP-8-29)
- Inflammatory breast cancer, *see* Micro-invasive and inflammatory breast cancer
- Integrins, 12 (PP-1-14), 25 (SY-4-2)
- Ki-67 index, 7 (SY-1-4), 25 (SY-4-1)
- Liver metastases, 51 (PP-8-15), 52 (PP-8-19), 54 (PP-8-31)
- Local recurrence: diagnosis and risk factors, 8 (SY-3-2, SY-3-1), 9 (SY-3-3), 14 (PP-2-2), 15 (PP-2-4), 21 (PP-3-6, PP-3-7, PP-3-5), 22 (PP-3-14), 23 (PP-3-15), 24 (PP-3-21, PP-3-23)
- Loss of heterozygosity, 7 (SY-1-3, SY-1-4)
- Lymph node biopsy, 28 (PP-4-10), 32 (PP-4-34)
- Lymph node positive breast cancer, 32 (PP-4-34), 34 (PP-5-1), 35 (PP-5-7), 39 (PP-6-6)
- Lymphatic dissemination, 15 (PP-2-7)
- Lymphoscintigraphy, 33 (PP-4-36)
- Magnetic resonance imaging, 8 (SY-2-2)
- Male breast cancer, 40 (PP-6-11)
- Mammography (*see also* Screening mammography), 23 (PP-3-18), 27 (PP-4-2, PP-4-1), 30 (PP-4-20), 32 (PP-4-29)
- Medullary and papillary breast cancer, 40 (PP-6-13), 55 (PP-9-1)
- Menarche, 28 (PP-4-11)
- Metastatic breast cancer: diagnosis, 30 (PP-4-19)
- Metastatic breast cancer: predictors of chemotherapeutic response, 11 (PP-1-8), 13 (PP-1-18), 14 (PP-1-24)
- Metastatic breast cancer: primary chemotherapy (*see also* specific regimens and agents), 1 (DI-3-1), 35 (PP-5-3), 47 (PP-7-10), 52 (PP-8-20), 55 (PP-8-34)
- Metastatic breast cancer: salvage chemotherapy (*see also* specific regimens and agents), 1 (DI-1-1, DI-1-2), 51 (PP-8-12), 55 (PP-8-34)
- MIB-1 index, 25 (SY-4-4, SY-4-1)
- Micro-infiltrative and inflammatory breast cancer, 18 (PP-2-19), 20 (PP-3-3), 22 (PP-3-14), 28 (PP-4-7), 30 (PP-4-20), 52 (PP-8-22), 54 (PP-8-32), 57 (PP-9-13), 58 (PP-9-16)
- Microvascular density, 14 (PP-1-23)
- Mucins, 25 (SY-4-3)
- nm23 protein expression, 55 (PP-9-2)
- Non-palpable breast lesions, 5 (EP-1), 14 (PP-1-26), 29 (PP-4-14, PP-4-13), 30 (PP-4-20)
- Obesity, 30 (PP-4-22)
- Oncogenes and gene amplification (*see also* more specific entries), 3 (PL-2), 7 (SY-1-3)
- Osteoporosis (*see also* Bone resorption), 26 (SY-6-3)
- <sup>32</sup>P radio-uptake, 40 (PP-6-14)
- p21/WAF1 expression, 55 (PP-9-3)
- p53 tumor suppressor gene, 3 (PL-2), 7 (SY-1-3, SY-1-4), 10 (PP-1-3), 41 (PP-6-19), 55 (PP-9-3, PP-9-1), 56 (PP-9-5, PP-9-7), 57 (PP-9-15)
- Parathyroid hormone-related protein, 53 (PP-8-26)
- Patient age, 17 (PP-2-18), 23 (PP-3-17), 24 (PP-3-22), 26 (SY-6-2, SY-6-1), 27 (PP-4-3), 34 (PP-4-41), 35 (PP-5-4)
- PCNA index, 25 (SY-4-1), 57 (PP-9-15), 58 (PP-9-17)
- Peritumoral emboli, 39 (PP-6-4)
- Physical examination, 15 (PP-2-4), 27 (PP-4-4), 29 (PP-4-12), 31 (PP-4-27), 32 (PP-4-33)

- Positron emission tomography, 29 (PP-4-17)
- Post-menopausal women, 17 (PP-2-18), 36 (PP-5-10), 49 (PP-8-3, PP-8-5, PP-8-2)
- Predictors of chemotherapeutic response (*see also* Biological markers, other more specific entries), 3 (PL-3), 5 (EP-4), 11 (PP-1-8), 13 (PP-1-18), 14 (PP-1-24), 39 (PP-6-8), 56 (PP-9-6)
- Predictors of outcome: mammography, 23 (PP-3-18), 27 (PP-4-1)
- Predictors of outcome: pathology (*see also* Biologic markers, other more specific entries), 13 (PP-1-21), 14 (PP-1-23), 39 (PP-6-4), 40 (PP-6-13)
- Predictors of outcome: tumor immunohistochemistry (*see also* Biologic markers, other more specific entries), 7 (SY-1-4), 11 (PP-1-6), 12 (PP-1-11), 13 (PP-1-21), 25 (SY-4-1, SY-4-4), 41 (PP-6-18), 55 (PP-9-2, PP-9-3, PP-9-1), 56 (PP-9-8), 57 (PP-9-14), 58 (PP-9-16)
- Pregnancy and breast cancer, 42 (PP-6-22)
- Progesterone receptor status, 13 (PP-1-20), 26 (SY-5-2), 30 (PP-4-22), 38 (PP-6-2), 41 (PP-6-19, PP-6-15, PP-6-18), 42 (PP-6-24)
- Prolactin receptors, 43 (SY-7-4)
- Protein tyrosine kinases, 57 (PP-9-10)
- pS2 (estrogen-inducible) protein expression, 13 (PP-1-22), 25 (SY-4-4), 41 (PP-6-18)
- Pyrimidine nucleoside phosphorylase, 57 (PP-9-14)
- Radiation exposure, 29 (PP-4-12)
- Radionuclide imaging, 30 (PP-4-19)
- Randomized clinical trials, 16 (PP-2-8), 17 (PP-2-16), 19 (PP-2-28), 21 (PP-3-8), 24 (PP-3-19), 31 (PP-4-28), 34 (PP-5-1), 35 (PP-5-5, PP-5-6), 36 (PP-5-9, PP-5-8)
- Recurrent breast cancer (*see also* Local recurrence), 13 (PP-1-17), 15 (PP-2-6), 21 (PP-3-5, PP-3-7)
- Reproductive status and reproductive interval, 28 (PP-4-9, PP-4-11), 36 (PP-5-10), 37 (PP-5-18), 42 (PP-6-22)
- Screening mammography, 1 (DI-2-1, DI-2-2), 5 (EP-1), 27 (PP-4-2, PP-4-1, PP-4-3, PP-4-4), 30 (PP-4-21), 31 (PP-4-27, PP-4-28, PP-4-25), 32 (PP-4-32, PP-4-33), 33 (PP-4-35), 34 (PP-4-41), 40 (PP-6-12)
- Secondary malignancies, 31 (PP-4-26)
- Skin metastasis, 46 (PP-7-8)
- Smoking and passive smoking exposure, 15 (PP-2-3), 28 (PP-4-11)
- Socioeconomic factors, 28 (PP-4-11)
- Sporadic breast cancer: patient characteristics, 29 (PP-4-15)
- Stereotaxic needle biopsy, *see* Breast biopsy
- Stromelysin-3 promoter, 10 (PP-1-2), 12 (PP-1-13)
- Thymidine phosphorylase, 14 (PP-1-23, PP-1-24)
- Thyroid dysfunction, 14 (PP-1-25)
- Toxicity of chemotherapy and radiation, 5 (EP-4), 22 (PP-3-9), 26 (SY-6-2), 45 (PP-7-4), 46 (PP-7-7, PP-7-9), 47 (PP-7-11, PP-7-12), 48 (PP-7-17), 52 (PP-8-20)
- TP53 protein accumulation, 11 (PP-1-7), 40 (PP-6-11)
- TPS, 31 (PP-4-23)
- Transferrin receptor (CD71), 12 (PP-1-11)
- Tumor antigens, 13 (PP-1-17), 31 (PP-4-23), 42 (PP-6-21)
- Tumor margins, 8 (SY-3-2, SY-3-1), 14 (PP-2-2), 23 (PP-3-18), 24 (PP-3-20)
- Tumor size, 23 (PP-3-15), 25 (SY-5-1), 32 (PP-4-31), 34 (PP-5-2), 36 (PP-5-9), 38 (PP-6-2), 39 (PP-6-4, PP-6-8)
- Tumor vascularity, 13 (PP-1-21)
- Ultrasound breast imaging, 29 (PP-4-14), 32 (PP-4-31), 41 (PP-6-16)
- Ultrasound lymph node imaging, 28 (PP-4-10), 32 (PP-4-34), 33 (PP-4-36)
- uPA (urokinase-type plasminogen activator), 10 (PP-1-3), 25 (SY-5-1), 55 (PP-9-4), 56 (PP-9-5)